title: [What are the therapeutic options for low HDL-cholesterol?].
abstract: HDL-cholesterol has a prognostic value for cardiovascular disease at least equivalent to that of LDL-cholesterol. Low levels of HDL-cholesterol constitute the principal dyslipidaemia in the general population, and this will be exacerbated with the predicted explosion in obesity and type 2 diabetes. The latter suggests that low HDL-cholesterol will become of even greater clinical concern. Raising HDL-cholesterol is not as yet considered a primary target for reducing risk of cardiovascular disease, but does constitute an aggravating factor in determining the treatment strategy. Serum HDL-cholesterol levels are variably responsive to lifestyle changes. Pharmacological therapy, which can lead to substantial increases in HDL, may be considered in high risk patients.
authors.affiliation: Service d'endocrinologie, diabétologie et nutrition, Département de médecine interne, HUG, 1211 Genève 14. Richard.James@hcuge.ch
authors.forename: Richard W
authors.initials: RW
authors.lastname: James
mesh_terms: D000924:Anticholesteremic Agents / Q000627:therapeutic use; D008076:Cholesterol, HDL / Q000097:blood*; D050171:Dyslipidemias / Q000628:therapy*; D006801:Humans; D008019:Life Style
chemical_list: D000924:Anticholesteremic Agents; D008076:Cholesterol, HDL